An Ultra-Fast Green UHPLC-MS/MS Method for Assessing the In Vitro Metabolic Stability of Dovitinib: In Silico Study for Absorption, Distribution, Metabolism, Excretion, Metabolic Lability, and DEREK Alerts
<i>Background and Objectives</i>: Dovitinib (DVB) is a pan-tyrosine kinase inhibitor (TKI) that can be administered orally. In September 2023, the FDA granted Oncoheroes approval to proceed with an Investigational New Drug (IND) application for dovitinib. This application is intended for the treatme...
Guardat en:
| Autors principals: | , , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
MDPI AG
2024-10-01
|
| Col·lecció: | Medicina |
| Matèries: | |
| Accés en línia: | https://www.mdpi.com/1648-9144/60/10/1626 |
| Etiquetes: |
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|